Ipamorelin Peptide 10mg – Selective Growth Hormone Secretagogue

Chemical diagram for Ipamorelin source: https://en.wikipedia.org/wiki/Ipamorelin#/media/File:Ipamorelin.svg

KEY SPECIFICATIONS:

PRODUCT OVERVIEW:

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that selectively binds to the Growth Hormone Secretagogue Receptor (GHS-R1a), also known as the ghrelin receptor. Unlike other GH-releasing peptides such as GHRP-2 or GHRP-6, Ipamorelin demonstrates exceptionally low cross-reactivity with other pituitary receptors. Consequently, it produces minimal effects on ACTH, cortisol, prolactin, FSH, LH, or TSH.

Furthermore, the structural architecture incorporates both natural and modified amino acids, including D-amino acids at strategic positions that protect against proteolytic cleavage. Specifically, the non-natural amino acid α-aminoisobutyric acid (Aib) at the N-terminal position provides additional stability and optimizes receptor binding affinity. Therefore, BIONIX supplies Ipamorelin with ≥99% HPLC-verified purity for selective GHS-R1a pharmacology research.

MECHANISM OF ACTION:

Ipamorelin operates through highly selective GHS-R1a receptor activation, thereby distinguishing it from broader-acting GH secretagogues.

Structural Design and Stability

Ipamorelin’s structure incorporates strategic modifications that enhance stability and receptor selectivity:

D-Amino Acid Protection: D-amino acids at positions 3 and 4 create stereochemical barriers that prevent recognition by proteolytic enzymes. As a result, biological half-life extends significantly compared to peptides composed exclusively of L-amino acids.

Aib (α-Aminoisobutyric Acid): The non-natural amino acid Aib at the N-terminus provides conformational constraints that optimize receptor binding. Additionally, it protects against aminopeptidase degradation.

GHS-R1a Signaling Pathway

The GHS-R1a receptor is a Class A G-protein-coupled receptor (GPCR) that primarily couples to Gq/11 proteins. Consequently, Ipamorelin activates the following cascade:

Molecular Cascade Details:

IP₃ Pathway: PLC-β hydrolyzes PIP₂ → IP₃ + DAG. Subsequently, IP₃ binds receptors on the endoplasmic reticulum, triggering calcium release. Consequently, calcium-dependent vesicle fusion occurs via SNARE proteins, resulting in GH exocytosis from somatotrophs.

DAG/PKC Pathway: DAG activates protein kinase C (PKC), which phosphorylates downstream targets. Furthermore, this pathway modulates ion channels and secretory machinery, thereby amplifying the secretory response.

Receptor Selectivity Profile

Ipamorelin demonstrates exceptional selectivity compared to other GH secretagogues. Therefore, researchers can isolate pure GHS-R1a effects:

Research Significance: This selectivity allows researchers to isolate GHS-R1a-mediated effects without confounding variables. Consequently, studies investigating pure GH secretion responses benefit from Ipamorelin’s clean pharmacological profile.

Downstream IGF-1 Effects

Ipamorelin-stimulated GH release leads to downstream effects mediated by insulin-like growth factor-1 (IGF-1):

RESEARCH APPLICATIONS:

Growth Hormone Signaling and Receptor Pharmacology

The primary research application of Ipamorelin lies in investigating GH release mechanisms. Specifically, researchers examine:

• Receptor Characterization: Ligand-receptor binding kinetics (Kd, Bmax), structure-activity relationships (SAR), receptor desensitization, and cross-talk with other GPCRs
• Signaling Analysis: Calcium flux (Fluo-4, Fura-2), IP₃ production quantification, PKC activation via phospho-antibodies, GH secretion (RIA, ELISA), and gene expression (qPCR)
• Dose-Response Studies: EC50 determination, maximal response characterization, temporal dynamics, and pulse amplitude/duration analysis

Body Composition and Metabolic Research

Experimental studies utilize Ipamorelin to investigate GH-IGF-1 axis effects. Furthermore, applications include:

• Muscle Research: Protein synthesis (mTOR pathway), satellite cell activation, myosin heavy chain expression, and myofibrillar formation
• Metabolic Studies: Glucose metabolism, insulin sensitivity, lipolysis in adipose tissue, hepatic glucose output, and energy expenditure
• Model Systems: Myocyte cultures (C2C12, primary cells), adipocyte differentiation models, whole-animal metabolic chambers, and body composition analysis (DEXA, MRI)

Musculoskeletal and Orthopedic Research

Ipamorelin enables investigation of GH axis roles in tissue regeneration. Consequently, applications include:

• Bone Research: Osteoblast differentiation, mineralization markers, osteocalcin expression, alkaline phosphatase activity, collagen type I synthesis, and bone density assessment
• Tendon and Ligament Studies: Fibroblast proliferation, collagen synthesis (types I, III), biomechanical properties, and healing process characterization
• Cartilage Investigation: Chondrocyte function, proteoglycan synthesis, aggrecan expression, collagen type II, and extracellular matrix maintenance

Furthermore, a 2026 PMC review highlights therapeutic peptides, including GH secretagogues, as emerging adjuncts in orthopedic injury management.

Gastrointestinal Motility Research

Moreover, emerging research investigates potential effects on GI motility:

• Smooth muscle contractility and enteric nervous system signaling
• Gastric emptying parameters and postoperative function models
• GHS-R1a expression in GI tissues and ghrelin pathway interactions
• Inflammatory mediator modulation in gut tissues

Neuroendocrine Research

Ipamorelin serves in studies of pituitary function and hypothalamic-pituitary axis regulation. Specifically:

• GH gene expression regulation and somatotroph secretory mechanisms
• Feedback loop characterization and GHRH/somatostatin interactions
• Receptor trafficking and internalization studies

However, all applications remain strictly limited to controlled laboratory research environments.

Comparative Analysis: Ipamorelin vs. Other GH Secretagogues

Selection Criteria:

• Choose Ipamorelin for: Isolated GHS-R1a studies, clean GH secretion research, selective receptor pharmacology, minimal confounding variables
• Choose GHRP-2/GHRP-6 for: Studies requiring broader hormonal activation, comparative selectivity research, multi-axis investigations

ANALYTICAL VERIFICATION:

BIONIX Ipamorelin undergoes comprehensive analytical characterization. Specifically:

• HPLC Analysis: ≥99% purity via reversed-phase chromatography with C18 columns, acetonitrile/water gradients, and TFA ion-pairing. Detection at 214 nm and 280 nm confirms aromatic amino acid content
• Mass Spectrometry: Electrospray ionization (ESI) or MALDI provides exact molecular weight confirmation (711.9 g/mol) and sequence verification. Furthermore, tandem MS/MS enables fragmentation analysis for complete sequence validation
• D-Configuration Verification: Confirmation of D-amino acid stereochemistry at positions 3 and 4
• Additional Parameters: Amino acid composition, residual solvent testing, water content (Karl-Fischer), endotoxin testing (LAL), and peptide content determination

Physical Characteristics:

DEVELOPMENT STATUS:

Ipamorelin is an established research compound with extensive pharmacological characterization:

• Discovery: 1998 (Raun et al., first selective GH secretagogue)
• Receptor: High-affinity GHS-R1a agonist with documented binding kinetics
• Mechanism: Well-characterized Gq/PLC signaling cascade
• Clinical Status: Research compound; not approved for therapeutic use
• Regulatory Note: WADA prohibited substance (growth hormone secretagogue category)
• Research Status: Extensively utilized in GH axis, receptor pharmacology, and metabolic studies
• Availability: BIONIX supplies exclusively for controlled laboratory research

Consequently, BIONIX Ipamorelin is intended exclusively for laboratory research applications.

FREQUENTLY ENCOUNTERED INQUIRIES:

What distinguishes Ipamorelin from other GHRPs? Ipamorelin demonstrates exceptional selectivity for the GHS-R1a receptor with minimal activity on other pituitary hormones. Specifically, it produces negligible effects on ACTH, cortisol, and prolactin compared to GHRP-2 and GHRP-6. Therefore, researchers can study GHS-R1a activation effects in isolation without confounding variables. Consequently, Ipamorelin provides the cleanest pharmacological profile among GH secretagogues.

What is the purity specification? All BIONIX Ipamorelin batches are HPLC-verified to ≥99% purity. Furthermore, each batch includes mass spectrometry confirmation (711.9 g/mol) and a batch-specific Certificate of Analysis. Additionally, D-configuration verification ensures proper stereochemistry at positions 3 and 4. Therefore, researchers receive a defined chemical agent with minimal impurities.

What are the primary research applications? Studies investigate Ipamorelin in GH signaling pathway research, body composition analysis, orthopedic/musculoskeletal applications, GI motility research, neuroendocrine studies, and receptor pharmacology. Moreover, applications extend to metabolic process investigation and tissue regeneration research. However, all uses remain strictly limited to laboratory environments.

How should Ipamorelin be stored? The lyophilized powder requires -20°C storage for long-term stability (up to 24 months). Additionally, protect from light and moisture. Furthermore, after reconstitution, store at 2-8°C and use within several days to 2 weeks. Consequently, proper storage maintains the D-amino acid configuration and peptide integrity essential for selective receptor binding.

How is Ipamorelin reconstituted for research protocols? Reconstitute in sterile bacteriostatic water or appropriate buffer. Specifically, add solvent slowly along the vessel wall and gently swirl rather than shake to prevent foam formation. Furthermore, excessive shaking can lead to aggregation or denaturation. Subsequently, visually inspect for clarity before use. Finally, store the reconstituted solution at 2-8°C with light protection.

Why is selectivity important for GH secretagogue research? Selective GHS-R1a activation enables researchers to isolate specific receptor-mediated effects. Unlike non-selective GHRPs that activate multiple hormone axes, Ipamorelin provides clean data on GHS-R1a signaling. Consequently, studies examining pure GH secretion, receptor pharmacology, or metabolic effects benefit from minimized confounding variables. Therefore, Ipamorelin represents the preferred choice for mechanistic GHS-R1a research.

REFERENCES:

• PMID: 9838201 — Svensson J et al., “Effects of the ghrelin receptor agonist ipamorelin on gastric emptying in rats,” J Endocrinol Invest, 1998.
• PMID: 9838202 — Raun K et al., “Ipamorelin, the first selective growth hormone secretagogue,” Eur J Endocrinol, 1998;139(5):552-561.
• PMID: 9928010 — Bowers CY et al., “Growth hormone-releasing peptide (GHRP),” Ann NY Acad Sci, 1998.
• PMID: 8778601 — Howard AD et al., “A receptor in pituitary and hypothalamus that functions in growth hormone release,” Science, 1996;273(5277):974-977.
• Ghigo E et al., “Growth hormone-releasing peptides,” Eur J Endocrinol, 1997;136(5):445-460.
• PMC 2026 — “Therapeutic Peptides in Orthopaedics: Applications, Challenges and Future Directions.”